Innate Pharma SA (IPHA)

Biological Products, (No Diagnostic Substances) · market cap $168M · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Innate Pharma SA (IPHA) is a French biological products company with 174 employees and a market cap of approximately $170M at a share price near $1.79. Its pipeline is led by MIS416 in Phase 2 for Secondary Progressive Multiple Sclerosis (SPMS) and includes IPH2101 in Phase 2 for Multiple Myeloma. No near-term catalysts are publicly calendared and key financial metrics — cash, runway, and dilution history — are not provided in the available data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
MIS416	Phase 2	Secondary Progressive Multiple Sclerosis
IPH2101	Phase 2	Multiple Myeloma

Price & technical context

3-month

-9.9%

6-month

+27.3%

12-month

-10.4%

52-wk range

$1.17–$2.54

vs 50-day MA

-16.8%

vs 200-day MA

-6.4%

Realized vol

87.8%

Max drawdown

-61.3%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for IPHA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.